High Noon Recalls Alcoholic Drinks Mislabeled as Celsius. What to Do if You Were Impacted
Cans that are filled with High Noon's vodka seltzer are mislabeled as Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition and have a silver top instead of a black top. High Noon discovered the error after receiving a shipment of empty Celsius cans instead of empty High Noon cans, according to a statement.
Distributors shipped these drinks to Florida, New York, Ohio, South Carolina, Virginia and Wisconsin between July 21 and 23.
Here's which lot codes were impacted and what to do if you bought (or drank) these cans of drink.
What to do if you were impacted by High Noon's drink recall
High Noon advises people who bought the following codes of Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition not to consume it and to discard it. The lot codes are L CCB 02JL25 2:55 to L CCB 02JL25 3:11. Other High Noon variety packs should not be affected.
High Noon reported that no illnesses or events occurred as a part of the mislabeling. If you've purchased the impacted drinks, contact High Noon Consumer Relations at consumerrelations@highnoonvodka.com for next steps and refunds. The recall is being conducted with the US Food and Drug Administration and the Alcohol and Tobacco Tax and Trade Bureau.
CNET reached out to High Noon for comment but did not receive an immediate response.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
38 minutes ago
- Medscape
Rectal Cancer Survival Not Tied to pCR
TOPLINE: According to a meta-analysis of randomized clinical trials (RCTs), pathologic complete response (pCR) was not associated with overall or disease-free survival in patients with rectal cancer, suggesting that the use of pCR as a surrogate endpoint for survival should be reexamined. METHODOLOGY: Neoadjuvant trials in rectal cancer are increasingly using pCR as a surrogate endpoint for long-term outcomes, following recommendations by the FDA in 2012. However, while some research has shown an association between pCR and improved survival in rectal cancer on the patient level, consensus on the trial-level validity of pCR as a surrogate is lacking. Researchers conducted a systematic review and meta-analysis of 25 RCTs involving 11,882 patients with rectal cancer who underwent neoadjuvant therapies (mostly chemo radiation) followed by surgical resection. The researchers assessed the correlation between pCR and both overall survival and disease-free survival. TAKEAWAY: Across trials that reported overall survival, weighted regression analysis revealed no correlation between pCR and overall survival (β, 0.37; 95% CI, -0.98 to 1.71; P = .57). Similarly, across trials reporting disease-free survival, there was no correlation between pCR and disease-free survival (β, -0.84; 95% CI, -2.55 to 0.87; P = .32). A sensitivity analysis conducted after excluding two studies with a high risk for bias also yielded null associations. The researchers performed subgroup analyses excluding studies that evaluated neoadjuvant radiation alone or included patients who did not receive curative resection and again found no association between pCR and either disease-free or overall survival. IN PRACTICE: 'Our trial-level analysis did not reveal a correlation between pCR and [disease-free survival] or [overall survival] in rectal cancer RCTs,' the authors of the study concluded. 'Our study's findings suggest a recommendation against using pCR as a [surrogate endpoint] for neoadjuvant therapies in rectal cancer until conclusive trial-level evidence of its association with long-term outcomes is firmly established.' SOURCE: This study, led by Kavin Sugumar, MD, Tulane University, New Orleans, and Jessica Jin Lie, MD, MPH, University of British Columbia, Vancouver, British Columbia, Canada, was published online in JAMA Network Open. LIMITATIONS: A subgroup analysis of total neoadjuvant therapy trials was not feasible due to insufficient sample size. Additionally, postsurgical therapies in patients without pCR may have improved outcomes, potentially diluting its association with survival. Mediation analysis was not possible due to lack of patient-level data. DISCLOSURES: The authors did not disclose any funding information. One author disclosed receiving personal fees from Novartis, consulting fees from Boehringer Ingelheim, and grants from Eli Lilly and Company and Taiho, outside the submitted work. Another author reported receiving royalties as a coauthor on several chapters of UpToDate. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
an hour ago
- Medscape
FDA Calls for Better Opioid Safety Labeling
The FDA is requiring manufacturers of opioid pain medications to update safety labels to better emphasize risks linked to their long-term use, the agency announced in a new Drug Safety Communication. The changes are based on observations from a May meeting between the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee, which met to discuss two postmarketing requirement studies that assessed risk for abuse, addiction, and overdose in long-term use of opioid analgesics. One of the observational studies showed that over 12 months of use, 1%-6% of the more than 2000 total participants met criteria for opioid addiction, 9% met criteria for prescription opioid abuse, and 22% met criteria for prescription opioid misuse. In the second study, 5-year cumulative incidence estimates for opioid overdose-related death ranged from 1.5%-4.0%. In addition, 17% of first opioid overdoses over the entire 5-11 year study period were fatal. The new safety-labeling requirements are a result of these findings, committee and public comments from the meeting, and recognition that there is currently an 'absence of adequate and well-controlled studies on long-term opioid effectiveness,' the FDA noted in a press release. 'The death of almost 1 million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,' FDA commissioner Marty Makary, MD, said in the release. 30-Day Warning The FDA has also called for a new prospective, randomized controlled trial to be conducted that will focus primarily on assessing risks and benefits of opioids used over the long term. For now, the updated labeling should include a better explanation of risks, stronger warnings about higher doses, clarification about use limits, an emphasis that long-acting or extended-release opioids should only be used if shorter-acting opioids or other medications have proven inadequate, and a reminder about serious harm that can come if a patient who becomes physically dependent does not stop opioid use. Additionally, the revised labels should provide information on possible opioid-related problems with the esophagus; on opioid overdose reversal agents; on toxic leukoencephalopathy, which can occur after overdose; and on negative drug-drug interactions, including gabapentinoids. 'This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and postmarket monitoring,' Makary said. The release noted that OxyContin's drug application was first approved without supportive long-term use data. The FDA added that manufacturers have 30 days to submit the newly required labeling updates for review.
Yahoo
an hour ago
- Yahoo
agilon health (AGL) Q2 Earnings: What To Expect
Healthcare services company Agilon Health (NYSE:AGL) will be announcing earnings results this Tuesday after the bell. Here's what to look for. agilon health beat analysts' revenue expectations by 1.8% last quarter, reporting revenues of $1.53 billion, down 4.5% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and EBITDA guidance for next quarter missing analysts' expectations significantly. It lost -36,000 customers and ended up with a total of 491,000. Is agilon health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting agilon health's revenue to be flat year on year at $1.47 billion, slowing from the 38.7% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.11 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. agilon health has missed Wall Street's revenue estimates five times over the last two years. Looking at agilon health's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts' expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health's stock price was unchanged. Read our full analysis of Select Medical's results here and CVS Health's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. agilon health is down 25.8% during the same time and is heading into earnings with an average analyst price target of $3.59 (compared to the current share price of $1.73). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
